Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1

BACKGROUND: Arsenic trioxide (ATO) is commonly used in the treatment of acute promyelocytic leukemia (APL), but does not benefit patients with solid tumors. When combined with other agents or radiation, ATO showed treatment benefits with manageable toxicity. Previously, we reported that metformin am...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Hematol Oncol
Auteurs principaux: Ling, Sunbin, Xie, Haiyang, Yang, Fan, Shan, Qiaonan, Dai, Haojiang, Zhuo, Jianyong, Wei, Xuyong, Song, Penghong, Zhou, Lin, Xu, Xiao, Zheng, Shusen
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2017
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5329912/
https://ncbi.nlm.nih.gov/pubmed/28241849
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-017-0424-0
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires